Cross-Sector entity

Zhenya Lindgardt

Person
6

Zhenya Lindgardt is most often covered alongside Sera Prognostics, which appears in 4 of these 4 stories. earnings accounts for 1 of the 4 tracked stories, while 3 other categories carry the remainder. Each carries 6 original sources on average.

4 verified stories tracked

Last mentioned: Mar 19, 2026

Entity pulse

Recent coverage · Zhenya Lindgardt

4 stories
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Zhenya Lindgardt

Zhenya Lindgardt is most often covered alongside Sera Prognostics, which appears in 4 of these 4 stories. earnings accounts for 1 of the 4 tracked stories, while 3 other categories carry the remainder. Each carries 6 original sources on average. We currently track 4 Cross-Sector stories that mention Zhenya Lindgardt, all published on March 19, 2026.

Stories tracked
4
Sources per story
6

Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Zhenya Lindgardt. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Runway Horizon

    Current capital projected to fund operations through significant commercial milestones.

  2. Cash Runway Limit

    Current capital projected to fund operations through this period across commercial milestones.

  3. 2026 Target

    Goal to reach 15-17 states and operate 5-7 live partner programs.

  4. Q4 Earnings Call

    Management outlines pivot from R&D to commercial scaling and state-level engagement.

  5. Sera Prognostics Commercial Pivot

    Announces target to reach 15-17 states and 60% of US births by year-end.

  6. Meta-Oklo Agreement

    Execution of 1.2GW Aurora power campus development in Ohio.

  7. Ecopetrol Dividend Proposal

    Board proposes COP 110 per share dividend representing 50% of net income.

  8. Oklo Capital Raise

    Raises $1.182 billion net through ATM program to fund Aurora projects.

  9. Fiscal Year End

    Sera concludes 2025 with $95.8M cash and successful PRIME study publication.

  10. Ecopetrol Production Peak

    Reports highest production in a decade at 751,000 boe/d.

Stories mentioning Zhenya Lindgardt 4

Startups market trends Positive 6

Strategic Endurance: Q4 Earnings Reveal a New Era for Venture-Scale Publics

The Q4 2025 earnings cycle highlights a critical shift for growth-stage public companies, where massive capital reserves and operational efficiency are being prioritized over immediate revenue. From Oklo's multi-billion dollar infrastructure plays to Sera Prognostics' clinical-milestone focus, the 'Strategic Endurance' model is now the primary driver of market sentiment.

6 sources
Finance earnings Positive 6

Q4 Earnings: Tech-Infra and Biotech Pivot as Retail Faces Margin Pressure

The Q4 2025 earnings cycle reveals a stark divergence between high-growth infrastructure bets and established retail and energy players navigating macroeconomic headwinds. While nuclear energy and biotech firms are securing massive capital for long-term deployments, consumer-facing giants like lululemon are grappling with regional stagnation and tariff-driven margin compression.

6 sources
Biotech pharma Positive 6

Sera Prognostics Leverages PRIME Study Success for 2028 Commercial Runway

Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. The company is pivoting toward large-scale commercialization of its PreTRM test following landmark PRIME study data showing a 56% reduction in very early preterm births.

6 sources
Healthcare medical devices Positive 6

Sera Prognostics Targets 2028 Runway as PRIME Study Bolsters Commercial Pivot

Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. Following the successful publication of its PRIME study—which demonstrated a 56% reduction in very preterm births—the company is aggressively shifting its focus toward state-level payer engagement and commercial scaling.

6 sources